

From: [Trials](#)
To: raynimrod@quinnemanuel.com; deborah.fishman@arnoldporter.com
Cc: [Matthew Traupman](#); [Landon Smith](#); david.caine@arnoldporter.com; alice.ho@arnoldporter.com; david.denuyl@arnoldporter.com; abigail.struthers@arnoldporter.com; [Trials](#)
Subject: IPR2023-00442 - Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Date: Thursday, April 18, 2024 12:20:31 PM

Counsel,

The Board requests that, at tomorrow's hearing and to the extent possible, the parties be prepared to argue before the panel why the exclusion criteria recited in independent claims 1 and 14 of the '681 patent should be construed as limiting upon the claims, particularly in view of the Board's previous Decision in IPR2022-01225. The Board is also prepared to authorize additional briefing upon this matter.

Regards,

Esther Goldschlager
Supervisory Paralegal Specialist
Patent Trial & Appeal Board
U.S. Patent & Trademark Office